Zealand Pharma A/S, a developer of peptide-based medicines, has appointed a new chief executive and embarked on a plan to restructure its portfolio in order to reduce operating expenses and free up money for research and development. Adam Steensberg will replace Emmanuel Dulac as CEO with a mandate to generate new pharmaceutical assets. Dr Steensberg has been promoted to CEO after having served as chief medical officer and vice president for research and development.
